<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202172</url>
  </required_header>
  <id_info>
    <org_study_id>AC009/18</org_study_id>
    <nct_id>NCT04202172</nct_id>
  </id_info>
  <brief_title>Functional Assessment of the Infart-related Artery With Bioactive and Polymer-free Coronary Stents (The FUNCOMBO Trial)</brief_title>
  <acronym>FUNCOMBO</acronym>
  <official_title>Six-month Endothelial and Microcirculatory Function of the Bioactive Sirolimus-eluting Combo Stent Versus the Polymer-free Biolimus-eluting Biofreedom Stent in Patients With ST-segment Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut d'Investigació Biomèdica de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sociedad Española de Cardiología</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut d'Investigació Biomèdica de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 50 patients with ST-elevation myocardial infarction (STEMI) undergoing
      primary-percutaneous coronary intervention (PPCI) will be randomized to two different
      coronary stents: BIOFREEDOM vs. COMBO stent.

      All patients will undergo to 6-month scheduled coronary angiography to evaluate the
      endothelial function response of the distal coronary segment and other functional parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The bioengineered COMBO stent (Orbus Neich, Fort Lauderdale, Florida, United States) has a
      dual-therapy strategy, which combines a sirolimus-eluting coating with an anti-CD34 antibody
      layer to promote vessel healing. Sirolimus release (5 μg/mm) is completed in 30 days, and the
      biodegradable polymer disappears within 90 days.

      CD34 antibodies are immobilized on the surface of the stent and capture circulating
      endothelial progenitor cells (EPCs). The captured EPCs are triggered by sheer stress from the
      circulating blood and other cell signals to differentiate and mature into endothelial cells.
      COMBO Plus is the only stent with a biological coating that actively repairs the vessel
      morphology. However, little is known regarding the endothelial function after stent
      implantation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 5, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function of the distal coronary segment of patients with myocardial infarction treated with two types of drug-eluting stents</measure>
    <time_frame>At 6 months of the stent implantation</time_frame>
    <description>To compare the mean lumen diameter changes to intracoronary acetyl-choline infusion of the distal coronary segment by quantitative coronary angiography between the COMBO stent vs. the BIOFREEDOM stent in STEMI patients. Endothelial dysfunction is defined as &gt;4% vasoconstriction to intracoronary acetylcholine compared to the 6-month baseline mean lumen diameter of the matched segment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Index of microcirculatory resistance</measure>
    <time_frame>At 6 months of the stent implantation</time_frame>
    <description>To compare the index of microcirculatory resistance (IMR) between the culprit arteries treated with COMBO vs. BIOFREEDOM in STEMI patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary flow reserve</measure>
    <time_frame>At 6 months of the stent implantation</time_frame>
    <description>To compare the coronary flow reserve (CFR) between the culprit arteries treated with COMBO vs. BIOFREEDOM in STEMI patients</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fractional flow reserve</measure>
    <time_frame>At 6 months of the stent implantation</time_frame>
    <description>To compare the fractional flow reserve (FFR) between the culprit arteries treated with COMBO vs. BIOFREEDOM in STEMI patients</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <condition>Coronary Microvascular Disease</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>BIOFREEDOM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation of Drug-eluting coronary stent without polymer in patients with myocardial infarction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COMBO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of Bioactive coronary stent in patients with myocardial infarction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stent implantation in the infart-related artery in patients with ST elevation myocardial infarction</intervention_name>
    <description>The 6-month scheduled coronary angiography will perform 3 interventions:
Endothelial function assessment with intracoronary acetyl-choline infusion.
Microcirculatory function assessment with a pressure wire during endovenous adenosine infusion.
Stent healing assessment using optical coherence tomography</description>
    <arm_group_label>BIOFREEDOM</arm_group_label>
    <arm_group_label>COMBO</arm_group_label>
    <other_name>All patients will undergo to 6-month coronary angiography after stent implantation in order to assess the endothelial and microvascular function of the infarct related artery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  STEMI &lt; 12 hours undergoing primary PCI.

          -  ST-segment elevation of &gt; 1mm in &gt; 2 contiguous leads, or (presumably new) left bundle
             branch block, or true posterior MI with ST depression of &gt;1mm in &gt;2 contiguous
             anterior leads.

          -  Presence of at least one acute infarct artery target vessel with one or more de-novo
             coronary artery stenosis in a native coronary artery within 2.75 - 3.75 mm reference
             vessel diameter and &lt; 24 mm length (visually estimated).

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  Female of childbearing potential (age &lt;50 years and last menstruation within the last
             12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy

          -  Known intolerance to aspirin, heparin, PLLA, everolimus, contrast material

          -  Cardiogenic Shock

          -  Unprotected left main coronary artery stenosis

          -  Distal occlusion of target vessel

          -  Acute myocardial infarction secondary to stent thrombosis

          -  Mechanical complications of acute myocardial infarction

          -  Severe tortuous, calcified or angulated coronary anatomy of the study vessel that in
             the opinion of the investigator would result in sub-optimal imaging or excessive risk
             of complication in the follow-up procedure

          -  Active bleeding or coagulopathy or patients at chronic anticoagulation therapy

          -  Chronic renal dysfunction with creatinine clearance &lt; 45 ml/minm2

          -  Subject is currently participating in another clinical trial that has not yet
             completed its primary endpoint
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep Gomez Lara, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge, L´Hospitalet de Llobregat, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neus Salvatella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Mar, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salvatore Brugaletta, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic, Barcelona, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 28, 2018</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut d'Investigació Biomèdica de Bellvitge</investigator_affiliation>
    <investigator_full_name>Josep Gomez Lara</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Microvascular Angina</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

